NewsRoom Articles - Page 2 of 242

FridayJun 26, 2026 10:00 am

US Health Care Expenditure Spiked to Nearly $6 Trillion in 2025

According to recent data released by CMS actuaries, spending on health care in the U.S. jumped to $5.7tn in 2025, the third consecutive year in which spending growth exceeded 7%. The data shows that one of the key drivers of this spike was pricey medications, such as GLP-1s, medications used to treat obesity. CMS actuaries note that this growth in spending stems from a number of factors that include people seeking more care and the uptake of expensive medications like the weight loss drugs mentioned earlier. Cost increases accounted for just a small fraction of this expenditure spike. Jacqueline Fiore, an economist working in the actuarial…

ThursdayJun 25, 2026 10:00 am

Researchers Urge Caution in Using Antibiotic Prophylaxis

The medical community has for long relied on antibiotic prophylaxis, the practice of prescribing antibiotics to safeguard at-risk individuals from bacterial infections. However, a new publication has sounded the alarm on the widespread use of these “just in case” treatments due to their risk of driving antibiotic resistance. The paper, published by researchers at Charles University in Prague, appeared in the Clinical Microbiology & Infection journal. The authors caution that the prophylactic use of antibiotics has become unsustainable due to its growing use by medical practitioners because it threatens the long term efficacy of these medications. As more people use these therapies, the risk of antimicrobial resistance is growing,…

ThursdayJun 25, 2026 9:45 am

Earth Science Tech Inc. (ETST) Presents Fiscal Year-End Financial Results for March 31, 2026, Operating a Diversified Holding Company Model

Earth Science Tech Inc. (OTC: ETST) recently reported year-end financial results for the fiscal year ending March 31, 2026 Earth Science Tech acquires, manages, and operates companies in pharmaceuticals, real estate, telemedicine, healthcare services, and other industries. Results include increases in revenue, gross profit, net income, and total assets. Earth Science Tech (OTC: ETST), a strategic holding company that acquires and manages a diverse portfolio of businesses, recently announced the financial results for the full fiscal year that ended on March 31, 2026 (https://ibn.fm/xRoIz). The reported results include: An 8% revenue increase compared to the year ended March 31, 2025,…

WednesdayJun 24, 2026 11:15 am

VERAXA Biotech AG (NASDAQ: VRXA) Advances BiTAC-ADC Platform as It Expands Next-Generation Cancer Therapy Pipeline

VERAXA Biotech has reported new in vitro proof-of-concept data supporting its BiTAC-ADC technology, demonstrating selective activity against cancer cells while sparing healthy cells in early testing. The company is presenting its BiTAC-ADC and BiTAC-TCE platforms for potential strategic collaborations at the BIO International Convention 2026. VERAXA’s proprietary BiTAC approach is designed to improve the precision of antibody-based cancer therapies by activating therapeutic effects only in targeted tumor cells. The company maintains a diversified oncology pipeline of antibody-based formats including antibody-drug conjugates (“ADCs”), T-cell engagers (“TCEs”), and other antibody-based formats. VERAXA recently began trading on the NASDAQ Capital Market under the…

WednesdayJun 24, 2026 10:30 am

Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF): Cancer Nanomedicine Enters a New Generation

Disseminated on behalf of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) and may include paid advertising. Cancer nanomedicine is emerging from an early period of skepticism, with more than 20 approved formulations now improving therapeutic index and patient quality of life during treatment Onco-Innovations’ lead drug candidate, ONC010, pairs a small-molecule PNKP inhibitor with a polymer nanodelivery system designed to extend circulation, increase drug retention in tumor, and improve tolerability Recent manufacturing updates, including kilogram-scale precursor production and a proposed Nanosoft Polymers collaboration, point to a sharpening focus on scalability, reproducibility, and regulatory readiness ahead of first-in-human studies For decades, chemotherapy has…

WednesdayJun 24, 2026 9:00 am

The Quest to Repair What Multiple Sclerosis Takes Away

BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) gradually strips people of command over their own bodies, advancing steadily with no available cure. More than 2.9 million people across the globe are currently living with the disease. But even with generations of scientific study and research, every approved treatment still falls short of one essential objective: bringing the disease to a complete stop. Existing therapies can slow its advance, but none can halt it outright. That shortfall translates into a future of mounting disability for millions of MS sufferers. Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (Profile) is determined working to change that…

WednesdayJun 24, 2026 9:00 am

Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market

BioMedWire Editorial Coverage: Oncology research is moving through one of its most active stretches in years. DNA Damage Response (“DDR”) inhibitors, a category of drugs that work by blocking cancer cells' capacity to fix their own damaged DNA, are growing well beyond the poly ADP ribose polymerase (“PARP”) inhibitor that first defined the category. DDR-inhibiting therapies generated an estimated $7 billion-plus in worldwide sales in 2025, and the wider oncology, diagnostics and precision medicine markets are expected to approach about $750 billion by 2030. A fresh wave of inhibitor classes is now taking shape as the next major opportunity. Standing at…

TuesdayJun 23, 2026 10:30 am

The $410 Billion Drug Delivery Revolution: Why Drug Delivery May Be the Next Major Frontier in Oncology Innovation

The rapidly expanding nanomedicine and advanced drug-delivery market is attracting growing attention as pharmaceutical companies seek ways to improve therapeutic performance without relying solely on costly new drug discovery programs. By addressing challenges such as poor bioavailability, inconsistent pharmacokinetics and limited tumor penetration, nanotechnology-based delivery systems may unlock additional value from existing oncology drugs. Oncotelic Therapeutics’ Deciparticle(TM) platform and Sapu003 program illustrate how innovative drug delivery approaches could help reshape the future of cancer treatment. The search for new cancer therapies has traditionally focused on discovering entirely new drug candidates. While this approach has produced important breakthroughs, it is also…

TuesdayJun 23, 2026 10:00 am

WashU Vaccine Could Revolutionize Personalized Glioblastoma Treatment

Researchers at Washington University (WashU) Medicine have conducted a small clinical trial testing a new vaccine against glioblastoma. The formulation was administered to nine patients who had undergone surgery and chemo-radiation therapy to remove their tumors. The results of this study show promise in extending tumor-free survival for a disease that is currently hard to treat. The study, whose findings appeared in Nature Cancer, sought to test a novel DNA platform that designs a personalized vaccine aimed at preventing glioblastoma tumors from recurring. Glioblastoma grows aggressively and patients rarely survive for more than a year or two after diagnosis, and scientists have been racing to develop new treatments that…

MondayJun 22, 2026 11:15 am

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Targets a $393 Billion Heart Disease Problem with Epigenetics and AI

For cardiovascular conditions, annual health care costs are forecasted to increase from $393 billion in 2020 to $1.4 trillion by 2050, almost quadrupling in size. What makes Cardio Diagnostics' approach distinct, and what gives the company a defensible clinical position, is its ability to detect coronary heart disease earlier and with high sensitivity. The company's recent commercial and regulatory milestones give additional shape to the investment thesis. Heart disease has held the grim distinction of being the leading cause of death in the United States for decades, and despite advances in medicine, the problem is getting worse, not better. According…